A phase I study of a novel IAP inhibitor APG-1387 as a monotherapy or in combination with pembrolizumab in treatments of patients with advanced solid tumors.
Drew Rasco(Texas Oncology), Yifan Zhai(Unknown), Zhiyan Liang(East China University of Science and Technology), Yuefen Tang, Alex Amaya(South Texas Accelerated Research Therapeutics), Dajun Yang(Ascendis Pharma (Denmark)), Yufeng Li(Jilin University of Finance and Economics), Jiao Ji(Sun Yat-sen University), Yingjie Huang, Hengbang Wang, Lichuang Men, Joan Sun
Cited by 11
Related Papers
Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
|Clinical Cancer Research|2015|799
Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial
|The Lancet Oncology|2017|780
First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers
|Journal of Clinical Oncology|2019|590
The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer
|Clinical Cancer Research|2012|432
LIGHT, a TNF-Like Molecule, Costimulates T Cell Proliferation and Is Required for Dendritic Cell-Mediated Allogeneic T Cell Response
|The Journal of Immunology|2000|402